Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 13/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441616 | 1.00 | SUV39H2 (0.56) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18386697 | 0.89 | SUV39H2 (0.50) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL15261599 | 0.85 | SMPD3 (0.46) | SUV39H2 | |
| SCHEMBL18386989 | 0.83 | MAP4K4 (0.54) | SUV39H2MAP4K4PDE10AJAK3BTK | |
| SCHEMBL14050863 | 0.81 | SUV39H2 (0.49) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL30716258 | 0.81 | CKS1B (0.52) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL14413671 | 0.80 | SUV39H2 (0.48) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL14050999 | 0.80 | SUV39H2 (0.48) | SUV39H2MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL15261712 | 0.80 | SMPD3 (0.52) | — | |
| SCHEMBL15261710 | 0.80 | SMPD3 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| EP-2834243-B1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXION PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXION PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| US-9403832-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403832-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-07-02 | — | — | US | disclosed |
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-07-02 | — | — | US | disclosed |
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946415-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | SUV39H2 4204/4885MAP4K4 82/4885CKS1B 453/4885 |
| US-20150183792-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | SUV39H2 3778/4885MAP4K4 188/4885CKS1B 185/4885 |
| US-20170129896-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | SUV39H2 3778/4885MAP4K4 188/4885CKS1B 185/4885 |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | SUV39H2 3778/4885MAP4K4 188/4885CKS1B 185/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | SUV39H2 4193/4885MAP4K4 75/4885CKS1B 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.